Reirradiation and hyperthermia for radiation-associated sarcoma
Marianne A A de Jong1, Sabine Oldenborg, S Bing Oei
1Department of Radiation Oncology and Hyperthermia, Academic Medical Center, Amsterdam, the Netherlands.
Cancer
|June 30, 2011
Summary
Reirradiation combined with hyperthermia shows promise for treating rare thoracic radiation-associated sarcomas (RAS). This approach achieved a 75% response rate in evaluable patients, suggesting feasibility and potential for durable local control.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Radiation-associated sarcoma (RAS) in the thoracic region is a rare but increasing complication with a poor prognosis.
- Effective treatment strategies for thoracic RAS remain limited.
Purpose of the Study:
- To evaluate the efficacy and feasibility of reirradiation combined with hyperthermia for thoracic radiation-associated sarcoma (RAS).
Main Methods:
- Retrospective analysis of 16 patients treated with reirradiation and hyperthermia for thoracic RAS between 1979 and 2009.
- Treatment was administered for unresectable disease (13 patients) or as adjuvant therapy post-resection (3 patients).
- Histological analysis revealed angiosarcoma in 69% of cases, with a median latency of 86 months.
Main Results:
- A 75% response rate was observed in 12 evaluable patients (7 complete, 2 partial responses).
- Median survival was 15.5 months.
- Six patients achieved durable local control, with follow-up ranging from 5 to 68 months.
Conclusions:
- Combined reirradiation and hyperthermia is a feasible treatment option for thoracic RAS.
- The observed high response rate and potential for durable local control indicate this combined modality is promising for managing this rare malignancy.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...